ADC Therapeutics (ADCT) Change in Receivables (2023 - 2026)

ADC Therapeutics has disclosed Change in Receivables across 4 years of filings, most recently posting $1.9 million for Q1 2026.

• Change in Receivables for Q1 2026 came in at $1.9 million, down 83.15% year-over-year; the trailing twelve-month figure through Mar 2026 was -$728000.0 (down 108.4% YoY), and the FY2025 annual result was $8.8 million, up 284.22% from the prior year.
• Change in Receivables came in at $1.9 million for Q1 2026 at ADC Therapeutics, down from $6.2 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $11.4 million in Q1 2025 to a low of -$48.9 million in Q1 2023.
• The 4-year median for Change in Receivables is -$319000.0 (2024), against an average of -$3.2 million.
• Peak annual rise in Change in Receivables reached 673.68% in 2025, while the deepest fall reached 1648.28% in 2025.
• ADC Therapeutics' Change in Receivables stood at $4.0 million in 2023, then slumped by 192.87% to -$3.7 million in 2024, then surged by 266.63% to $6.2 million in 2025, then sank by 68.84% to $1.9 million in 2026.
• The last three Change in Receivables figures came in at $1.9 million (Q1 2026), $6.2 million (Q4 2025), and -$3.3 million (Q3 2025), per Business Quant data.